Jiuling Yang

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X _L

Degradation of proteins by PROTACs and other strategies

Advances in targeted degradation of endogenous proteins

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Targeted protein degradation: expanding the toolbox

PROTAC targeted protein degraders: the past is prologue

In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)

Harnessing the Power of Proteolysis for Targeted Protein Inactivation

Crystal Structures of Protein-Bound Cyclic Peptides

PROTAC-DB: an online database of PROTACs

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality

Current strategies for the design of PROTAC linkers: a critical review

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Abstract 4870: Targeted MDM2 degradation as a novel and efficacious cancer therapy

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction